An experimental drug may protect heart function in people with Duchenne muscular dystrophy, a fatal genetic disorder that progressively weakens muscles. A new study shows Setanaxib preserved cardiac performance in preclinical models of the disease.
The research, published in Molecular Therapy, found the drug limited heart enlargement and reduced tissue scarring, both critical in preventing heart failure.
How the drug works
Setanaxib targets NOX1 and NOX4, enzymes that generate reactive molecules tied to oxidative stress. These molecules serve normal functions, but excessive levels trigger inflammation and fibrosis, harming muscle tissue over time.
Blocking NOX4 helped maintain the heart’s pumping ability. The approach also reduced activity in genes linked to cardiomyopathy, a severe heart condition common in Duchenne patients.
Da-Zhi Wang, the study’s lead researcher and director of the Center for Regenerative Medicine at the University of South Florida Health Heart Institute, described the results as promising. His team has studied the disease’s progression for over 15 years, identifying biological pathways that could lead to new treatments.
The heart’s role in Duchenne
Duchenne muscular dystrophy primarily affects boys, caused by mutations on the X chromosome that prevent dystrophin production. This protein is essential for muscle stability. Without it, muscle cells break down with use, replaced by fat and scar tissue.
The heart faces unique risks. Unlike skeletal muscles, it contracts continuously, making damage unavoidable. As the disease advances, the heart enlarges and weakens, often resulting in heart failure, a leading cause of death in these patients.
Treatment advances have extended lifespans, but protecting the heart has become more urgent. Existing therapies, including gene replacement, help but don’t fully address cardiac complications.
Related: Carbon Capture Could Trim Data Center Emissions
John Mably, an associate professor at USF Health and a study co-author, noted Setanaxib has already undergone trials for lung fibrosis and kidney and liver disease. “We hope it will soon be tested in Duchenne patients to slow heart disease progression,” he said.
The drug’s potential extends beyond Duchenne. The findings indicate NOX4 may serve as a target for other cardiomyopathy forms, though additional research is required to confirm broader applications.
Gabriela Diniz, an assistant professor on the team, highlighted how basic science drives medical progress. These efforts help explain human disease and improve healthcare outcomes.
The study emerges as Duchenne research expands beyond muscle function. With patients living longer, attention has turned to managing secondary complications, especially heart-related ones. While still in early testing, the drug offers a possible way to slow one of the disease’s deadliest effects.
Setanaxib’s established safety record in other conditions may speed its path to Duchenne trials. Researchers stress more work is needed to confirm human effectiveness. If successful, it could join therapies aimed at preserving heart function in a disease where time is precious.
Larger preclinical studies will likely follow, then carefully designed human trials. For now, the drug provides hope in a field with few treatment options.
Wildfire smoke has also been linked to changes in bird sightings in affected regions.